Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity |
Investigator |
Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Examining Global Gene Expression in Skin Biopsies from People with Hypermobile EDS | Grant | $69,020.00 | Research | Christina Laukaitis | Medicine | Ehlers-Danlos Society | 03/2020 |
| A Multicenter, Double-Blind, RanDomized, Placebo-Controlled, Parallel-Group Study to determine the EffIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects with Fabry Disease | Contract | $85,957.00 | Clinical Trial | Christina Laukaitis | Medicine | Idorsia Pharmaceutical (Switzerland) | 11/2020 |
| Health Assessment - Consultative Examinations (CE) | Contract | $252,806.00 | Other Sponsored Activity | Christina Vasquez | Arthritis Center-Research | Arizona Department of Economic Security | 01/2021 |
| Establishing Strategies to Ameliorate Amyloid Pathology in Light Chain Amyloidosis | Grant | $329,045.00 | Research | Christopher Glembotski | COM Phx Campus Administration | Scripps Research Institute | 09/2021 |
| New Translational Research Platform Using Gene Sequencing and Stem Cells To Diagnose and Treat Atrial Fibrillation (AF) | Grant | $167,051.45 | Research | Christopher Glembotski | COM Phx Campus Administration | University of Arizona Foundation | 01/2022 |
| Non-canonical ERAD as a Regulator of Cardiac Hypertrophy | Grant | $2,459,972.00 | Research | Christopher Glembotski | COM Phx Campus Administration | National Heart, Lung, and Blood Institute | 01/2022 |
| The ER Stress-Induced Selenoprotein, SelenoS, Regulates Proteostasis and Cardiac Hypertrophy | Grant | $1,237,307.00 | Research | Christopher Glembotski | COM Phx Campus Administration | National Heart, Lung, and Blood Institute | 01/2021 |
| ATF6 is Required for ANP Secretion from the Heart | Grant | $729,125.00 | Research | Christopher Glembotski | COM Phx Campus Administration | National Heart, Lung, and Blood Institute | 12/2020 |
| Harnessing the Adaptive ER Stress Response in Myocardial Ischemia | Grant | $349,932.00 | Research | Christopher Glembotski | COM Phx Campus Administration | National Heart, Lung, and Blood Institute | 12/2020 |
| IPA for Chase Irwin | Contract | $64,549.00 | Research | Christopher Glembotski | COM Phx Campus Administration | United States Department of Veterans Affairs | 03/2022 |
| FLowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH) | Contract | $125,613.76 | Clinical Trial | Christopher Goettl | COM Phx Radiology | Inari Medical | 02/2020 |
| DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease | Grant | $3,770,471.00 | Research | Christopher Hulme | Pharmacology and Toxicology | National Institute on Aging | 04/2020 |
| University of Michigan O'Brien Kidney Translation Core Center | Grant | $39,125.00 | Research | Chyi Chyi Chong | Medicine | University of Michigan | 03/2021 |
| VA Medical Educational Costs | Ancillary Contract - Residency Programs | $61,636.00 | Instruction | Conrad Clemens | COM Academic Affairs | United States Department of Veterans Affairs | 06/2021 |
| Defining the role of PIM kinases in hypoxia-induced prostate cancer invasion | Fellowship | $92,072.00 | Research Training | Corbin Jensen | Cellular & Molecular Medicine | National Cancer Institute | 02/2022 |
| A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Through 5 Years of Age | Contract | $421,673.20 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Vertex Pharmaceuticals, Incorporated | 08/2021 |
| Standardizing Treatment of Pulmonary Exacerbations in Pediatrics (STOP-PEDS) Pilot Funding Request (STUDY) | Contract | $60,516.00 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Indiana University | 05/2021 |
| A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal F | Contract | $587,778.40 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Vertex Pharmaceuticals, Incorporated | 03/2022 |
| A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous f | Contract | $577,503.72 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Vertex Pharmaceuticals, Incorporated | 03/2022 |
| Training Long Term - Pediatric Pulmonary Centers | Grant | $1,700,000.00 | Instruction | Cori Daines | Pediatrics | Health Resources and Services Administration | 05/2020 |
| A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older | Contract | $484,469.00 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Vertex Pharmaceuticals, Incorporated | 02/2022 |
| A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... | Contract | $273,767.50 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Janssen Research & Development, LLC | 01/2020 |
| A Phase 1/2a Randomized, Double-blind, Two-part, Dose-ascending, Multicenter Study of the Safety and Pharmacokinetics of Ar-501 (Gallium Citrate), Administered via Inhalation, in Healthy Adult and P. | Contract | $408,060.92 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Aridis Pharmaceuticals Inc. | 10/2021 |
| A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People with Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY) | Contract | $34,865.00 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Seattle Children's Hospital | 11/2020 |
| CF Learning Network: Implementation Phase | Grant | $48,496.00 | Research | Cori Daines | Pediatrics | Cincinnati Children's Hospital Medical Center | 04/2020 |